HYPEBEAST(00150.HK)終止擬與Iron Spark(ISAA.US)合併協議
HYPEBEAST(00150.HK)公布,有關擬通過與特殊目的收購公司Iron Spark(ISAA.US)合併,在納斯達克和聯交所雙重上市的交易,緊隨最後截止日期後,公司於昨日(28日)收市後向Iron Spark發出書面通知,指公司根據合併協議第10.1(c)條即時終止合併協議,惟並無損害公司的任何權利、權力、特權、補償及現有或隨後產生的辯護。
由於終止合併協議,有關交易(包括合併事項、私人配售、額外私人配售、紅股發行及股份合併)將不會進行,且不會向股東寄發通函。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.